Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

Drury’s ASX stag, MetroGlass’s new owner, and more
Markets Small Cap Wrap

Drury’s ASX stag, MetroGlass’s new owner, and more

Rod Drury goes ‘pre-revenue’ again, plus small cap news from NZ.

Listed property firms welcome ‘Investment Boost'
Property

Listed property firms welcome ‘Investment Boost'

The tax policy could translate into millions in extra cash.

NZX down as property company gets key renewal
Markets Market Close

NZX down as property company gets key renewal

ASB Bank has extended the lease for its downtown Auckland site for another nine years.

Tom Raynel 03 Jul 2025
Anna Scott joining Mercer
Markets

Anna Scott joining Mercer

Former Smart boss will replace current Mercer chief executive Martin Lewington.

Staff reporters 03 Jul 2025